DALI: Vitamin D and lifestyle intervention for gestational diabetes mellitus (GDM) prevention: An European multicentre, randomised trial - study protocol

Authors

Judith G.M. Jelsma, Amsterdam UMC - Free University Amsterdam
Mireille N.M. van Poppel, Amsterdam UMC - Free University Amsterdam
Sander Galjaard, KU Leuven– University Hospital Leuven
Gernot Desoye, Medizinische Universität Graz
Rosa Corcoy, Hospital de La Santa Creu I Sant Pau
Roland Devlieger, KU Leuven– University Hospital Leuven
Andre van Assche, KU Leuven– University Hospital Leuven
Dirk Timmerman, KU Leuven– University Hospital Leuven

Document Type

Article

Publication Date

7-5-2013

Journal

BMC Pregnancy and Childbirth

Volume

13

URL with Digital Object Identifier

10.1186/1471-2393-13-142

Abstract

Background: Gestational diabetes mellitus (GDM) is an increasing problem world-wide. Lifestyle interventions and/or vitamin D supplementation might help prevent GDM in some women.Methods/design: Pregnant women at risk of GDM (BMI≥29 (kg/m2)) from 9 European countries will be invited to participate and consent obtained before 19+6 weeks of gestation. After giving informed consent, women without GDM will be included (based on IADPSG criteria: fasting glucose<5.1mmol; 1 hour glucose <10.0 mmol; 2 hour glucose <8.5 mmol) and randomized to one of the 8 intervention arms using a 2×(2×2) factorial design: (1) healthy eating (HE), 2) physical activity (PA), 3) HE+PA, 4) control, 5) HE+PA+vitamin D, 6) HE+PA+placebo, 7) vitamin D alone, 8) placebo alone), pre-stratified for each site. In total, 880 women will be included with 110 women allocated to each arm. Between entry and 35 weeks of gestation, women allocated to a lifestyle intervention will receive 5 face-to-face, and 4 telephone coaching sessions, based on the principles of motivational interviewing. The lifestyle intervention includes a discussion about the risks of GDM, a weight gain target <5kg and either 7 healthy eating 'messages' and/or 5 physical activity 'messages' depending on randomization. Fidelity is monitored by the use of a personal digital assistance (PDA) system. Participants randomized to the vitamin D intervention receive either 1600 IU vitamin D or placebo for daily intake until delivery. Data is collected at baseline measurement, at 24-28 weeks, 35-37 weeks of gestation and after delivery. Primary outcome measures are gestational weight gain, fasting glucose and insulin sensitivity, with a range of obstetric secondary outcome measures including birth weight.Discussion: DALI is a unique Europe-wide randomised controlled trial, which will gain insight into preventive measures against the development of GDM in overweight and obese women. © 2013 Jelsma et al.; licensee BioMed Central Ltd.